Introduction
A considerable proportion of all patient safety events concern medication errors [1] . Even though many of these events do not result in adverse patient outcomes, serious patient harm or even loss of life may occur. Studies have estimated that 5 -12 % percent of all hospital admissions are related to problematic use of pharmaceuticals [2, 3] . Among the possible types of medication errors, administration errors are often mentioned as common and often leading to patient harm [4, 5, 6] and can occur due to errors by either patients or health care professionals.
Administration errors include dosing at the wrong time, by the wrong route or with too high or too low doses that could contribute to harm. Here we describe a case of an administration error with subsequent overdose in a patient treated with the acetylcholine esterase inhibitor rivastigmine patches for dementia.
Case report
This case was reported to the Regional Pharmacovigilance Centre in Linköping, which is a collaboration between the county councils in the Southeast region of Sweden and the Medical Products Agency in Sweden.
The report described an 87-year old male with dementia. The patient was treated with rivastigmine patches services personnel found the man on the floor in his home. When lifting him into his bed, the staff noticed that he had six rivastigmine patches (Exelon 9,5 mg/24 h) attached to the upper part of his body. The recommended [7] , and prescribed, dose was one patch at a time that should be changed every 24 h. Blood pressure was 114/62 and pulse 101 bpm. The staff described, however, that he was administered six patches the day before this event, and that these patches were changed to six new patches in the morning by the same person. Misinterpretation of the patient information leaflet accompanying the patch (figure 1) was the reason for this mistake according to the staff. In retrospect the staff described that the patient after the application of the first six patches suffered from nausea, vomiting and confusion but this was not put into relation with the use of the drug at that time point. All patches were removed and after consulting a physician it was decided that the man should stay in his home with more frequent visits to monitor blood pressure and pulse. In case of bradycardia a physician should be contacted.
Three hours after removing the patches the blood pressure was 150/80 mmHg and pulse 106 bpm. At a visit 9 hours (1 a.m.) after removing the patches the man was again found on the floor. Furnishing and decorations had been torn down and the man had scrape wounds on arms, knees and the forehead. The man was conscious but dizzy, the pulse was fluctuating with a frequency of 45 bpm. Blood pressure was 120/80 mmHg. Thereafter the man was transferred by ambulance to the emergency department of the nearby county hospital.
On admittance to the emergency he was in his usual state not showing any clinical signs of rivastigmine overdose, but serum creatinine was 149 mol/L and he presented signs of urinary tract infection, a rivastigmine labelled adverse drug reaction described in the Exelon Summary Product Characteristics (SPC). During the following days he developed acute renal failure with increased potassium levels and decreased calcium. Despite that efforts were made to adjust salt and fluid balance, the condition progressively deteriorated with serum creatinine rising to 1035 mol/L and urea 80 mmol/L. The patient died in hospital 19 days after the overdose.
The terminal cause of death was considered uremia from an acute tubular necrosis that was assessed as a result of dehydration through vomiting .The treatment with the rivastigmine patches were assessed as having caused or contributed to the dehydrated condition.
Discussion
In this case unintentional and inappropriate use of multiple patches of rivastigmine is described. The same day as the first six patches were applied the patient presented typical signs of dose-related rivastigmine adverse drug reactions such as confusion and nausea [7] . In another case [8] an overdose due to a medication error similar to the one we describe in this report is described. In that case a 80-year-old woman with dementia who presented to a hospital emergency department complaining of light-headedness, vomiting, diarrhoea and lower extremity muscle pain, all well known side effects of rivastigmine. Examination showed fasciculations and miotic pupils.
On her body nine rivastigmine patches (Exelon ® , 9,5 mg/24 h) were found. It was determined that the patient placed the nine patches on her body 5 days prior to this event and that the symptoms gradually increased during this period. She was discharged 3 days later in a stable condition. In two published cases of oral overdoses typical signs of cholinergic syndrome including dizziness, vomiting, salivation, miosis and cardiac and respiratory effects are described [9, 10] . In both these cases the patients also presented with transient bradycardia, as is described in our case. Moreover, rivastigmine has in clinical trials been associated with renal failure, which was part of the symptoms presenting in the case we describe [11] .
The adverse reactions presented by the patient after application of the six patches should have warranted further examination of the patient, or contact with a physician to clarify the cause of the symptoms. Increased effort to ascertain a high standard of knowledge in the group of healthcare and home care services personnel is important for a safe use of drugs. It is also important to increase early detection rate of adverse drug reactions that could be potentially serious.
Transdermal patches have been described as one way to increase compliance in Alzheimer patients [12] . In the case of rivastigmine, patches have been shown to provide similar efficacy and increased tolerability compared to rivastigmine capsules [13] . Furthermore, the aspect of convenience for caregivers and patients have been questioned, especially since application of rivastigmine patches to the exact same skin location should be avoided within 14 days according to the SPC instruction [14] . Since significant amounts of active substance can still be present in the patch at the intended time of change [15] the use of patches warrants extra care to avoid administration of multiple doses. The risk of medication errors of this type is likely to be especially high when administration of the patch is made by different individuals over time and at different locations on the body surface.
Mistakes with application of multiple patches have been described for patches for pain relief [16, 17] . This shows that use of this administration route is prone to this specific type of error, especially since the treatment often is indicated in patients with advanced age or patients whose medication is controlled by ambulatory teams with frequent change of staff members. During the same year two additional reports with multiple rivastigmine patches were sent to the Regional Pharmacovigilance Centre in Linköping suggesting that the case described in this report is not an isolated event (unpublished data). In both these cases health care personnel observed two patches at the same time attached to the patients body when changing rivastigmin patches. In these cases no adverse drug reactions were described. The type of spontaneous adverse drug reaction reports described here indicates that such systems for pharmacovigilance monitoring can be used not only for establishing the safety of the drug itself, but also to find medication handling problems. Moreover, the described case stresses the importance of unambiguous labelling to ascertain a safe use of drugs. Following the report of this case the manufacturer was contacted by the Swedish Medical Products Agency to start a process of clarifying the information regarding dosing and application of the rivastigmine patches. This has now resulted in the decision by the European Medicines Agency to update the SPC with strict information about only using one patch at a time. This will hopefully reduce the risk for similar misinterpretations in the future. 
Figure legend
Illustration from Exelon patches SPC indicating suitable areas to attach a patch.
